Medication overuse headache
| Medication overuse headache | |
|---|---|
| Other names | Rebound headache |
| Specialty | Neurology |
A medication overuse headache (MOH), also known as a rebound headache, usually occurs when painkillers are taken frequently to relieve headaches.[1] These cases are often referred to as painkiller headaches.[2] Rebound headaches frequently occur daily, can be very painful and are a common cause of chronic daily headache. They typically occur in patients with an underlying headache disorder such as migraine or tension-type headache that "transforms" over time from an episodic condition to chronic daily headache due to excessive intake of acute headache relief medications. MOH is a serious, disabling and well-characterized disorder, which represents a worldwide problem and is now considered the third-most prevalent type of headache. The proportion of patients in the population with Chronic Daily Headache (CDH) who overuse acute medications ranges from 18% to 33%. The prevalence of medication overuse headache (MOH) varies depending on the population studied and diagnostic criteria used. However, it is estimated that MOH affects approximately 1-2% of the general population, but its relative frequency is much higher in secondary and tertiary care.[3]
Classification
[edit]Medication overuse headache is a recognized ICHD (International Classification of Headache Disorders) classification.[4] Over the years different sets of diagnostic criteria have been proposed and revised by the major experts of headache disorders. The term MOH first appeared in the ICHD 2nd edition in 2004. It was defined as a secondary headache, with the aim of emphasising excessive drug intake as the basis of this form of headache. The two subsequent revisions of the diagnostic criteria for MOH (2005 and 2006) refined and extended the definition of the condition on the basis of both its chronicity (headache on more than 15 days/month for more than three months) and drug classes, thereby identifying the main types of MOH. In the case of ergotamine, triptans, opioids and combination medications in particular, intake on > 10 days/month for > 3 months is required, whereas simple analgesics are considered overused when they are taken on > 15 days/month for >3 months.[5]
Causes
[edit]MOH is known to occur with frequent use of many different medications, including most commonly: triptans,[6] ergotamines,[7] simple and combination analgesics,[8][9] and opioids.[10] Common over-the-counter medicines that can cause headaches when overused include Excedrin Migraine, Cafergot, and Advil.[11][12] Dietary and medicinal caffeine consumption appears to be a modest risk factor for chronic daily headache onset, regardless of headache type.[13][14]
A lifelong history of headaches is a major risk factor for MOH.[15] MOH is very rare in patients without a history of recurrent headaches, and it rarely develops in patients who take analgesics for non-headache pain, like arthritis or irritable bowel syndrome. Furthermore, MOH is more probable when a family history of MOH is present, thus indicating a genetic susceptibility. It is thought that rebound headaches are caused by a neuronal re-adjustment process. Analgesic intake raises the pain threshold. Thus, lacking pain stimuli for longer times, the brain re-calibrates to experience normal stimuli as pain.[16]
The time it takes for someone to develop medication overuse headaches (MOH) after taking medication too often depends on the type of medication they are using. If someone is taking triptans (such as Sumatriptan etc.), it may take about 1.7 years for them to develop MOH. If they are taking ergots (such as Ergotamine etc.), it may take about 2.7 years, and if they are taking analgesics (such as Naproxen etc.), it may take about 4.8 years. So, the delay between taking medication too often and developing MOH varies based on the type of medication being used.[17]
The underlying mechanisms that lead to the development of the condition are still widely unknown and clarification of their role is hampered by a lack of experimental research or suitable animal models. Various pathophysiological abnormalities have been reported and they seem to have an important role in initiating and maintaining chronic headache (genetic disposition, receptor and enzyme physiology and regulation, psychological and behavioural factors, physical dependencies, recent functional imaging results).[18]
In some cases, individuals may be genetically predisposed to developing medication overuse headache.[19] A PET study in patients with chronic analgesic overuse showed decreased activity in the orbitofrontal cortex of the brain, which is also seen in substance abuse. This suggests that there may be an underlying neurological susceptibility to addiction in some individuals. However, more research is needed to fully understand the complex interplay of factors that contribute to the development of MOH.[17][20]
Headache treatment
[edit]Opioids and butalbital are sometimes inappropriately used as treatment for migraine and headache and should be avoided in favor of more effective, migraine-specific treatments.[21][22] Opioid and butalbital use can worsen headaches and cause MOH.[21] When a patient fails to respond to other treatment or migraine specific treatment is unavailable, then opioids may be used.[22]
Regular use of over-the-counter drugs (OTC) such as paracetamol and NSAIDs can also be a cause of MOH.[23] OTC medication for headache should be limited to use for not more than two days weekly,[23] and it is recommended to seek medical counsel when any pain lasts more than a few days. Concurrent with MOH, overuse of acetaminophen (known as paracetamol in some countries) for treating headaches risks causing liver damage and NSAID overuse can cause gastrointestinal bleeding.[23]
Prevention
[edit]In general, any patient who has frequent headaches or migraine attacks should be considered as a potential candidate for preventive medications instead of being encouraged to take more and more painkillers or other rebound-causing medications. Preventive medications are taken on a daily basis. Some patients may require preventive medications for many years; others may require them for only a relatively short period of time such as six months. Effective preventive medications have been found to come from many classes of medications including neuronal stabilizing agents (aka anticonvulsants), antidepressants, antihypertensives, and antihistamines. Some effective preventive medications include Elavil (amitriptyline), Depakote (valproate), Topamax (topiramate), and Inderal (propranolol).[medical citation needed][24]
Treatment
[edit]MOH is common and can be treated. The overused medications must be stopped for the patient's headache to resolve, though there is limited evidence to suggest this can be done without using other preventive measures.[9] Clinical data shows that the treatment of choice is abrupt drugs withdrawal, followed by starting prophylactic therapy.[25] However, the discontinuation of overused drugs may lead to the initial worsening of headaches, nausea, vomiting, sleep disturbance, anxiety, and restlessness.[9] These symptoms greatly depend on the previously overused drugs and typically last from two to ten days. They are relieved by the further intake of the overused medication, which might reinforce the continuation of overuse and noncompliance toward discontinuation. Where physical dependence or a rebound effect such as rebound headache is possible, gradual reduction of medication may be necessary.[26] It is important that the patient's physician be consulted before abruptly discontinuing certain medications as such a course of action has the potential to induce medically significant physical withdrawal symptoms. Abruptly discontinuing butalbital, for example, can actually induce seizures in some patients, although simple over the counter analgesics can safely be stopped by the patient without medical supervision. A long-acting analgesic/anti-inflammatory, such as naproxen (500 mg twice a day), can be used to ease headache during the withdrawal period.[27][28] Two months after the completion of a medication withdrawal, patients with MOH typically notice a marked reduction in headache frequency and intensity.[29]
Drug withdrawal is performed very differently within and across countries. Most physicians prefer inpatients programmes, however effective drug withdrawal may also be achieved in an outpatient setting in uncomplicated MOH patients (i.e. subjects without important co-morbidities, not overusing opioids or ergotaminics and who are at their first detoxification attempt). In the absence of evidence-based indications, in MOH patients the choice of preventive agent should be based on the primary headache type (migraine or TTH), on the drug side-effect profile, on the presence of co-morbid and co-existent conditions, on patient's preferences, and on previous therapeutic experiences.[30]
Following an initial improvement of headache with the return to an episodic pattern, a relevant proportion (up to 45%) of patients relapse, reverting to the overuse of symptomatic drugs.[31][32]
Predictors of the relapse, and that could influence treatment strategies, are considered the type of primary headache, from which MOH has evolved, and the type of drug abused (analgesics, and mostly combination of analgesics, but also drugs containing barbiturates or tranquillisers cause significantly higher relapse rates), while gender, age, duration of disease and previous intake of preventative treatment do not seem to predict relapse rate.[citation needed]
MOH is clearly a cause of disability and, if not adequately treated, it represents a condition of risk of possible co-morbidities associated to the excessive intake of drugs that are not devoid of side-effect. MOH can be treated through withdrawal of the overused drug(s) and by means of specific approaches that focus on the development of a close doctor-patient relationship in the post-withdrawal period.[33]
History
[edit]Rebound headache was first described by Dr. Lee Kudrow in 1982.[34]
See also
[edit]References
[edit]- ^ Garza, Ivan; Robertson, Carrie E.; Smith, Jonathan H.; Whealy, Mark E. (2022). "102. Headache and other craniofacial pain". In Jankovic, Joseph; Mazziotta, John C.; Pomeroy, Scott L. (eds.). Bradley and Daroff's Neurology in Clinical Practice. Vol. II. Neurological disorders and their management (8th ed.). Edinburgh: Elsevier. p. 1756. ISBN 978-0-323-64261-3.
- ^ "Medically unexplained symptoms". nhs.uk. 19 October 2017. Retrieved 29 March 2021.
- ^ Colás, R.; Muñoz, P.; Temprano, R.; Gómez, C.; Pascual, J. (2004-04-27). "Chronic daily headache with analgesic overuse: Epidemiology and impact on quality of life". Neurology. 62 (8): 1338–1342. doi:10.1212/01.WNL.0000120545.45443.93. ISSN 0028-3878. PMID 15111671. S2CID 27740384.
- ^ "The International Headache Classification". ihs-classification.org. International Headache Society. Archived from the original on 4 March 2016. Retrieved 28 June 2014.
- ^ Ashina, Sait; Terwindt, Gisela M.; Steiner, Timothy J.; Lee, Mi Ji; Porreca, Frank; Tassorelli, Cristina; Schwedt, Todd J.; Jensen, Rigmor H.; Diener, Hans-Christoph; Lipton, Richard B. (2023-02-02). "Medication overuse headache". Nature Reviews Disease Primers. 9 (1): 5. doi:10.1038/s41572-022-00415-0. ISSN 2056-676X. PMID 36732518. S2CID 43144437.
- ^ "The International Classification of Headache Disorders". ihs-classification.org. The International Headache Society. Retrieved 28 June 2014.
- ^ "The International Classification of Headache Disorders". ihs-classification.org. The International Headache Society. Archived from the original on 18 November 2012. Retrieved 28 June 2014.
- ^ "The International Classification of Headache Disorders". ihs-classification.org. The International Headache Society. Retrieved 28 June 2014.
- ^ a b c Chiang, Chia-Chun; Schwedt, Todd J; Wang, Shuu-Jiun; Dodick, David W (2016). "Treatment of medication-overuse headache: A systematic review". Cephalalgia. 36 (4): 371–386. doi:10.1177/0333102415593088. ISSN 0333-1024. PMID 26122645. S2CID 36144020.
- ^ "The International Classification of Headache Disorders". ihs-classification.org. The International Headache Society. Retrieved 28 June 2014.
- ^ "Excedrin Migraine Is Back on the Shelves — But Is It Good for Migraine?". migraineagain.com.
- ^ MD, Sait Ashina (2019-11-07). "Stopping the vicious cycle of rebound headaches". Harvard Health. Retrieved 2024-08-20.
- ^ Scher, Ann I.; Stewart, Walter F.; Lipton, Richard B. (2004). "Caffeine as a risk factor for chronic daily headache: A population-based study". Neurology. 63 (11): 2022–2027. doi:10.1212/01.WNL.0000145760.37852.ED. PMID 15596744. S2CID 25344474.
- ^ Bulletin, Drug Therapeutics (2010). "Management of medication overuse headache". Drug and Therapeutics Bulletin. 340: c1305. doi:10.1136/bmj.c1305. PMID 20427444. S2CID 220110431. Retrieved 11 April 2018.
- ^ "Medication overuse headaches - Symptoms and causes". Mayo Clinic. Retrieved 2024-08-20.
- ^ Saxhaug Kristoffersen, Esper; Lundqvist, Christofer (2014). "Medication-overuse headache: a review". Journal of Pain Research. 7: 367–378. doi:10.2147/JPR.S46071. PMC 4079825. PMID 25061336.
- ^ a b "Medication Overuse Headache: What are the Causes, Symptoms, Diagnosis, Treatment, and Prevention". Retrieved 2023-04-27.
- ^ Goadsby, Peter J.; Holland, Philip R.; Martins-Oliveira, Margarida; Hoffmann, Jan; Schankin, Christoph; Akerman, Simon (2017-04-01). "Pathophysiology of Migraine: A Disorder of Sensory Processing". Physiological Reviews. 97 (2): 553–622. doi:10.1152/physrev.00034.2015. ISSN 0031-9333. PMC 5539409. PMID 28179394.
- ^ Kristoffersen, Espen Saxhaug; Lundqvist, Christofer (2014-04-04). "Medication-overuse headache: epidemiology, diagnosis and treatment". Therapeutic Advances in Drug Safety. 5 (2): 87–99. doi:10.1177/2042098614522683. ISSN 2042-0986. PMC 4110872. PMID 25083264.
- ^ Fumal, Arnaud; Laureys, Steven; Di Clemente, Laura; Boly, Mélanie; Bohotin, Valentin; Vandenheede, Michel; Coppola, Gianluca; Salmon, Eric; Kupers, Ron; Schoenen, Jean (2005-12-05). "Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine". Brain. 129 (2): 543–550. doi:10.1093/brain/awh691. ISSN 1460-2156. PMID 16330505.
- ^ a b Consumer Reports Health Best Buy Drugs (21 August 2012), "Treating Migraine Headaches: Some Drugs should rarely be used" (PDF), Drugs for Migraine Headaches (AAN), Yonkers, New York: Consumer Reports, retrieved 28 October 2013
- ^ a b American Academy of Neurology (February 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Academy of Neurology, retrieved August 1, 2013, which cites
- Silberstein, S. D. (2000). "Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 55 (6): 754–762. doi:10.1212/WNL.55.6.754. PMID 10993991.
- Evers, S.; Afra, J.; Frese, A.; Goadsby, P. J.; Linde, M.; May, A.; Sándor, P. S.; European Federation of Neurological Societies (2009). "EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force". European Journal of Neurology. 16 (9): 968–981. doi:10.1111/j.1468-1331.2009.02748.x. PMID 19708964. S2CID 9204782.
- Institute for Clinical Systems Improvement (2011), Headache, Diagnosis and Treatment of, Institute for Clinical Systems Improvement
- ^ a b c American Headache Society (September 2013), "Five Things Physicians and Patients Should Question", Choosing Wisely: an initiative of the ABIM Foundation, American Headache Society, archived from the original on 6 December 2013, retrieved 10 December 2013, which cites
- Bigal, M. E.; Serrano, D.; Buse, D.; Scher, A.; Stewart, W. F.; Lipton, R. B. (2008). "Acute Migraine Medications and Evolution from Episodic to Chronic Migraine: A Longitudinal Population-Based Study". Headache: The Journal of Head and Face Pain. 48 (8): 1157–1168. doi:10.1111/j.1526-4610.2008.01217.x. PMID 18808500.
- Bigal, M. E.; Lipton, R. B. (2008). "Excessive acute migraine medication use and migraine progression". Neurology. 71 (22): 1821–1828. doi:10.1212/01.wnl.0000335946.53860.1d. PMID 19029522. S2CID 36285728.
- Zwart, J. A.; Dyb, G.; Hagen, K.; Svebak, S.; Holmen, J. (2003). "Analgesic use: A predictor of chronic pain and medication overuse headache: The Head-HUNT Study". Neurology. 61 (2): 160–164. doi:10.1212/01.WNL.0000069924.69078.8D. PMID 12874392. S2CID 11357203.
- Silberstein, S. D. (2000). "Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 55 (6): 754–762. doi:10.1212/WNL.55.6.754. PMID 10993991.
- ^ Kumar, Anil; Kadian, Renu (2024), "Migraine Prophylaxis", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 29939650, retrieved 2024-08-16
- ^ Fischer, Michelle A.; Jan, Arif (2024), "Medication-Overuse Headache", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 30844177, retrieved 2024-08-20
- ^ de Filippis S, Salvatori E, Farinelli I, Coloprisco G, Martelletti P (2007). "Chronic daily headache and medication overuse headache: clinical read-outs and rehabilitation procedures". Clin Ter. 158 (4): 343–7. PMID 17953286.
- ^ Silberstein SD, McCrory DC (2001). "Butalbital in the treatment of headache: history, pharmacology, and efficacy". Headache. 41 (10): 953–67. doi:10.1046/j.1526-4610.2001.01189.x. PMID 11903523. S2CID 27684961.
- ^ Loder E, Biondi D (September 2003). "Oral phenobarbital loading: a safe and effective method of withdrawing patients with headache from butalbital compounds". Headache. 43 (8): 904–9. doi:10.1046/j.1526-4610.2003.03171.x. PMID 12940814. S2CID 36000736.
- ^ Zeeberg P, Olesen J, Jensen R (June 2006). "Probable medication-overuse headache: the effect of a 2-month drug-free period". Neurology. 66 (12): 1894–8. doi:10.1212/01.wnl.0000217914.30994.bd. PMID 16707727. S2CID 23088630.
- ^ Tassorelli, C; Jensen, R; Allena, M; De Icco, R; Sances, G; Katsarava, Z; Lainez, M; Leston, Ja; Fadic, R; Spadafora, S; Pagani, M; Nappi, G; the COMOESTAS Consortium (2014-08-03). "A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study". Cephalalgia. 34 (9): 645–655. doi:10.1177/0333102414521508. ISSN 0333-1024. PMID 24558185.
- ^ Tassorelli, C; Jensen, R; Allena, M; De Icco, R; Sances, G; Katsarava, Z; Lainez, M; Leston, Ja; Fadic, R; Spadafora, S; Pagani, M; Nappi, G; the COMOESTAS Consortium (February 20, 2014). "A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study". Cephalalgia. 34 (9): 645–655. doi:10.1177/0333102414521508. ISSN 0333-1024. PMID 24558185.
- ^ "Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study". researchgate.net. September 5, 2008.
- ^ Vandenbussche, Nicolas; Laterza, Domenico; Lisicki, Marco; Lloyd, Joseph; Lupi, Chiara; Tischler, Hannes; Toom, Kati; Vandervorst, Fenne; Quintana, Simone; Paemeleire, Koen; Katsarava, Zaza (2018-12-01). "Medication-overuse headache: a widely recognized entity amidst ongoing debate". The Journal of Headache and Pain. 19 (1): 50. doi:10.1186/s10194-018-0875-x. ISSN 1129-2369. PMC 6043466. PMID 30003412.
- ^ Kudrow L (1982). "Paradoxical effects of frequent analgesic use". Adv Neurol. 33: 335–41. PMID 7055014.
Bibliography
[edit]- Diener HC, Limmroth V (August 2004). "Medication-overuse headache: a worldwide problem". Lancet Neurol. 3 (8): 475–83. doi:10.1016/S1474-4422(04)00824-5. PMID 15261608. S2CID 43840120.
- Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G (May 2003). "Rates and predictors for relapse in medication overuse headache: a 1-year prospective study". Neurology. 60 (10): 1682–3. doi:10.1212/01.wnl.0000063322.14078.90. PMID 12771266. S2CID 22923813.
- International Headache Society (2004). "The International Classification of Headache Disorders: 2nd edition". Cephalalgia. 24 (Suppl 1): 9–160. doi:10.1111/j.1468-2982.2004.00653.x. PMID 14979299.
- Olesen J, Bousser MG, Diener HC, et al. (June 2006). "New appendix criteria open for a broader concept of chronic migraine". Cephalalgia. 26 (6): 742–6. doi:10.1111/j.1468-2982.2006.01172.x. PMID 16686915. S2CID 4834124.
- Ghiotto N, Sances G, Galli F, et al. (February 2009). "Medication overuse headache and applicability of the ICHD-II diagnostic criteria: 1-year follow-up study (CARE I protocol)". Cephalalgia. 29 (2): 233–43. doi:10.1111/j.1468-2982.2008.01712.x. PMID 19025549. S2CID 7534798.
- Silberstein SD, Olesen J, Bousser MG, et al. (June 2005). "The International Classification of Headache Disorders, 2nd Edition (ICHD-II)--revision of criteria for 8.2 Medication-overuse headache". Cephalalgia. 25 (6): 460–5. doi:10.1111/j.1468-2982.2005.00878.x. PMID 15910572. S2CID 19666440.